ClinicalTrials.gg
CompletedNCT02561585Updated Mar 6, 2025Results posted

LEO 124249 Ointment in the Treatment of Alopecia Areata

A Phase 2 interventional study of LEO 124249 and Vehicle in Alopecia Areata, sponsored by LEO Pharma. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
45th of 84
40 · median 46
Started
2016
with 4 others
Phase 2
42 of 98
8 open now
Registered
26th of 98
by date

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 45th largest by enrollment of the 84 interventional ones that give a count, is one of 5 that started in 2016, is one of 42 in phase 2, and was the 26th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.

Read the detailed description

The objectives of this clinical trial are to compare the efficacy of twice-daily topical LEO 124249 30 mg/g ointment with LEO 124249 ointment vehicle for 12 weeks in the treatment of hair loss in subjects with alopecia areata, to evaluate the safety of this treatment, to evaluate hair regrowth, to determine subject quality of life, and to explore disease mechanism and its biomarkers.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have signed and dated after receiving verbal and written information about the clinical trial.
  • Subjects with unequivocal clinical diagnosis of moderate to severe scalp alopecia areata (patch type, totalis, universalis), as determined by the (sub) investigator, affecting a minimum of 30% scalp area at Visit 1 (Screening) and Visit 2 (Day 1, baseline).
  • Minimum 6 month duration of hair loss at Visit 1 (Screening). No upper limit time limit.
  • Subject must accept to not cut hair in the treated scalp areas during the trial.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant or are breast feeding.
  • Current signs of spontaneous hair regrowth.
  • Diffuse type alopecia areata.
  • Co-existing moderate to severe androgenic alopecia (Norwood-Hamilton stage IV-VI and Ludwig stage II and III)
  • Subjects with changed or expected changes in medication for thyroid disease within 6 month before Visit 1 (screening) or during the trial.
  • Systemic treatment with drugs (e.g. methotrexate, cyclosporine, azathioprine), chloroquin derivatives, , or any other systemic therapy that in the opinion of the investigator could affect hair regrowth, within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    LEO 124249

    LEO 124249 ointment 30 mg/g twice daily

    Drug: LEO 124249

  • Placebo comparator
    Vehicle

    LEO 124249 ointment vehicle twice daily

    Other: Vehicle

Interventions

  • Also known as: LEO 124249 Ointment

  • OtherVehicle

    Also known as: LEO 124249 Vehicle

06

What researchers measure

Primary outcomes

  1. Change in Severity of Alopecia Areata Tool (SALT) Score

    The SALT score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

    Time frame: From baseline (Day 1) to Week 12 (Day 84)

Secondary outcomes

  1. Summary of Absolute SALT Score

    The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. Summary of observed values of the absolute SALT score.

    Time frame: At baseline (Day 1), Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  2. Summary of Change in SALT Score

    The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

    Time frame: From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)

  3. Summary of Relative Change in SALT Score

    The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

    Time frame: From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)

  4. Percentage of Patients Who Achieve 50% Improvement in the SALT Score

    The event of having at least 50% reduction in SALT score at Week 12 (Day 84) as compared to baseline (Day 1)

    Time frame: At Week 12 (Day 84)

  5. Hair Length

    Hair length measured in millimeters.

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  6. Hair Growth Rate

    Change in hair length measured in millimeters per day.

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  7. Relative Hair Thickness

    Thickness relative to participant's normal scalp hair. Relative assessment not applicable for participants with alopecia areata totalis and universalis.

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  8. Hair Type

    Hair type being either vellus hair or terminal hair. Hair type is not applicable for participants with alopecia areata totalis and universalis.

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  9. Hair Color

    Absolute color of hair. Hair color is not applicable for alopecia areata totalis and universalis.

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  10. Global Assessment of Overall Hair Regrowth Compared to Baseline

    Based on standardized photographs

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  11. Participant's Global Assessment of Hair Regrowth

    The participant will assess the hair regrowth before the investigator does any assessments of hair regrowth.

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

  12. Subcategory and Total Score of the Alopecia Areata Quality of Life Questionnaire (AA-QLI)

    The scale includes 21 questions measuring the degree to which the patient was affected by the AA in the last month, scored from 1 (not affected at all) to 4 (highly affected). The AA-QLI transformed scores for each of the subcategories 'subjective symptoms', 'relationship' and 'objective signs' ranging from (min-max) 9-36, 9-36, and 3-12. Total score ranges from 0-84. Low score indicating that the participant was least affected by AA.

    Time frame: At baseline (Day 1) and at Week 12 (Day 84)

  13. Treatment Satisfaction Questionnaire for Medication Score

    The Treatment Satisfaction Questionnaire for Medication (TSQM II) is a validated, general measure of treatment satisfaction for medication - accounting for effectiveness, side effects, convenience, and global satisfaction - that is comparable across medication types and patient conditions. The individual derived score for each of the 4 dimensions (effectiveness, side effects, convenience, and global satisfaction) of the TSQM II questionnaire ranged from 0-100, with a higher score indicating greater satisfaction to treatment.

    Time frame: At Week 12 (Day 84)

07

Results

Posted Apr 16, 2019

Participant flow

Date of First Subject First Visit: 02-Feb-2016 Date of Last Subject Last Visit: 06-Dec-2016

Participant flow — Overall Study
MilestoneLEO 124249LEO 124249 Vehicle
Started2011
Completed176
Not completed35

Outcome measures

PrimaryChange in Severity of Alopecia Areata Tool (SALT) Score

The SALT score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

Time frame:
From baseline (Day 1) to Week 12 (Day 84)
Reported as:
Mean · units on a scale
Change in Severity of Alopecia Areata Tool (SALT) Score
units on a scaleLEO 124249LEO 124249 Vehicle
Change in Severity of Alopecia Areata Tool (SALT) Score-3.8 ± 9.3-3.4 ± 17.0
Statistical analysis
  • LEO 124249 vs LEO 124249 Vehicle · t-test, 2 sided · p = 0.97 (t-test in a baseline adjusted linear model) · Mean difference (final values): -0.20 · 95% CI -12.05 to 11.65t-test, 2 sided on a 5% level
SecondarySummary of Absolute SALT Score

The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. Summary of observed values of the absolute SALT score.

Time frame:
At baseline (Day 1), Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Mean · units on a scale
Summary of Absolute SALT Score
units on a scaleLEO 124249LEO 124249 Vehicle
Baseline (Day 1)67.2 ± 25.174.4 ± 24.3
Week 4 (Day 28)63.1 ± 26.771.0 ± 25.9
Week 8 (Day 56)62.7 ± 27.568.6 ± 31.2
Week 12 (Day 84)61.2 ± 28.966.4 ± 38.0
SecondarySummary of Change in SALT Score

The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

Time frame:
From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)
Reported as:
Mean · units on a scale
Summary of Change in SALT Score
units on a scaleLEO 124249LEO 124249 Vehicle
Baseline (Day 1) to Week 4 (Day 28)-2.2 ± 4.40.0 ± 1.3
Baseline (Day 1) to Week 8 (Day 56)-2.5 ± 7.3-1.5 ± 9.6
Baseline (Day 1) to Week 12 (Day 84)-3.8 ± 9.3-3.4 ± 17.0
SecondarySummary of Relative Change in SALT Score

The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

Time frame:
From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)
Reported as:
Mean · percentage change
Summary of Relative Change in SALT Score
percentage changeLEO 124249LEO 124249 Vehicle
Baseline (Day 1) to Week 4 (Day 28)-4.6 ± 9.0-0.3 ± 2.3
Baseline (Day 1) to Week 8 (Day 56)-5.6 ± 17.8-5.3 ± 16.9
Baseline (Day 1) to Week 12 (Day 84)-7.7 ± 22.3-9.1 ± 32.5
SecondaryPercentage of Patients Who Achieve 50% Improvement in the SALT Score

The event of having at least 50% reduction in SALT score at Week 12 (Day 84) as compared to baseline (Day 1)

Time frame:
At Week 12 (Day 84)
Reported as:
Count of participants · Participants
Percentage of Patients Who Achieve 50% Improvement in the SALT Score
ParticipantsLEO 124249LEO 124249 Vehicle
Yes21
No155
SecondaryHair Length

Hair length measured in millimeters.

Time frame:
At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Mean · mm
Hair Length
mmLEO 124249LEO 124249 Vehicle
Week 4 (Day 28)12.7 ± 17.05.6 ± 8.4
Week 8 (Day 56)18.2 ± 21.710.3 ± 16.9
Week 12 (Day 84)25.1 ± 31.816.3 ± 23.5
SecondaryHair Growth Rate

Change in hair length measured in millimeters per day.

Time frame:
At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Mean · mm/day
Hair Growth Rate
mm/dayLEO 124249LEO 124249 Vehicle
Week 4 (Day 28)0.4 ± 0.70.1 ± 0.2
Week 8 (Day 56)0.2 ± 0.30.1 ± 0.5
Week 12 (Day 84)0.3 ± 0.80.1 ± 0.5
SecondaryRelative Hair Thickness

Thickness relative to participant's normal scalp hair. Relative assessment not applicable for participants with alopecia areata totalis and universalis.

Time frame:
At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Count of participants · Participants
Relative Hair Thickness
ParticipantsLEO 124249LEO 124249 Vehicle
Week 4 (Day 28) — Much thinner101
Week 4 (Day 28) — Slightly thinner10
Week 4 (Day 28) — Same thickness00
Week 8 (Day 56) — Much thinner61
Week 8 (Day 56) — Slightly thinner11
Week 8 (Day 56) — Same thickness10
Week 12 (Day 84) — Much thinner41
Week 12 (Day 84) — Slightly thinner11
Week 12 (Day 84) — Same thickness10
SecondaryHair Type

Hair type being either vellus hair or terminal hair. Hair type is not applicable for participants with alopecia areata totalis and universalis.

Time frame:
At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Count of participants · Participants
Hair Type
ParticipantsLEO 124249LEO 124249 Vehicle
Week 4 (Day 28) — Terminal hair41
Week 4 (Day 28) — Velus hair92
Week 8 (Day 56) — Terminal hair42
Week 8 (Day 56) — Velus hair91
Week 12 (Day 84) — Terminal hair61
Week 12 (Day 84) — Velus hair62
SecondaryHair Color

Absolute color of hair. Hair color is not applicable for alopecia areata totalis and universalis.

Time frame:
At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Count of participants · Participants
Hair Color
ParticipantsLEO 124249LEO 124249 Vehicle
Week 4 (Day 28) — Black41
Week 4 (Day 28) — Blond21
Week 4 (Day 28) — Brown30
Week 4 (Day 28) — Gray00
Week 4 (Day 28) — Red00
Week 4 (Day 28) — White51
Week 8 (Day 56) — Black41
Week 8 (Day 56) — Blond10
Week 8 (Day 56) — Brown40
Week 8 (Day 56) — Gray01
Week 8 (Day 56) — Red00
Week 8 (Day 56) — White51
Week 12 (Day 84) — Black40
Week 12 (Day 84) — Blond10
Week 12 (Day 84) — Brown20
Week 12 (Day 84) — Gray00
Week 12 (Day 84) — Red10
Week 12 (Day 84) — White43
SecondaryGlobal Assessment of Overall Hair Regrowth Compared to Baseline

Based on standardized photographs

Time frame:
At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Count of participants · Participants
Global Assessment of Overall Hair Regrowth Compared to Baseline
ParticipantsLEO 124249LEO 124249 Vehicle
Week 4 (Day 28) — Much worse00
Week 4 (Day 28) — Moderately worse10
Week 4 (Day 28) — Slightly worse11
Week 4 (Day 28) — Unchanged158
Week 4 (Day 28) — Slightly improved20
Week 4 (Day 28) — Moderately improved00
Week 4 (Day 28) — Much improved00
Week 8 (Day 56) — Much worse00
Week 8 (Day 56) — Moderately worse01
Week 8 (Day 56) — Slightly worse20
Week 8 (Day 56) — Unchanged145
Week 8 (Day 56) — Slightly improved20
Week 8 (Day 56) — Moderately improved01
Week 8 (Day 56) — Much improved00
Week 12 (Day 84) — Much worse01
Week 12 (Day 84) — Moderately worse00
Week 12 (Day 84) — Slightly worse20
Week 12 (Day 84) — Unchanged94
Week 12 (Day 84) — Slightly improved50
Week 12 (Day 84) — Moderately improved11
Week 12 (Day 84) — Much improved00
SecondaryParticipant's Global Assessment of Hair Regrowth

The participant will assess the hair regrowth before the investigator does any assessments of hair regrowth.

Time frame:
At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Reported as:
Count of participants · Participants
Participant's Global Assessment of Hair Regrowth
ParticipantsLEO 124249LEO 124249 Vehicle
Week 4 (Day 28) — No regrowth86
Week 4 (Day 28) — <25% of regrowth83
Week 4 (Day 28) — 25%-49% of regrowth20
Week 4 (Day 28) — 50%-74% of regrowth00
Week 4 (Day 28) — 75%-99% of regrowth00
Week 4 (Day 28) — 100% of regrowth00
Week 8 (Day 56) — No regrowth85
Week 8 (Day 56) — <25% of regrowth81
Week 8 (Day 56) — 25%-49% of regrowth01
Week 8 (Day 56) — 50%-74% of regrowth20
Week 8 (Day 56) — 75%-99% of regrowth00
Week 8 (Day 56) — 100% of regrowth00
Week 12 (Day 84) — No regrowth63
Week 12 (Day 84) — <25% of regrowth81
Week 12 (Day 84) — 25%-49% of regrowth11
Week 12 (Day 84) — 50%-74% of regrowth21
Week 12 (Day 84) — 75%-99% of regrowth00
Week 12 (Day 84) — 100% of regrowth00
SecondarySubcategory and Total Score of the Alopecia Areata Quality of Life Questionnaire (AA-QLI)

The scale includes 21 questions measuring the degree to which the patient was affected by the AA in the last month, scored from 1 (not affected at all) to 4 (highly affected). The AA-QLI transformed scores for each of the subcategories 'subjective symptoms', 'relationship' and 'objective signs' ranging from (min-max) 9-36, 9-36, and 3-12. Total score ranges from 0-84. Low score indicating that the participant was least affected by AA.

Time frame:
At baseline (Day 1) and at Week 12 (Day 84)
Reported as:
Mean · units on a scale
Subcategory and Total Score of the Alopecia Areata Quality of Life Questionnaire (AA-QLI)
units on a scaleBaseline: LEO 124249Baseline: LEO 124249 VehicleWeek 12: LEO 124249Week 12: LEO 124249 Vehicle
Subjective symptoms25.9 ± 4.924.3 ± 5.525.5 ± 4.423.7 ± 7.3
Relationship18.7 ± 6.817.5 ± 6.718.7 ± 7.216.8 ± 7.5
Objective signs7.8 ± 2.48.4 ± 2.26.9 ± 2.37.7 ± 2.7
Total score52.3 ± 12.150.2 ± 11.151.1 ± 12.548.2 ± 15.2
SecondaryTreatment Satisfaction Questionnaire for Medication Score

The Treatment Satisfaction Questionnaire for Medication (TSQM II) is a validated, general measure of treatment satisfaction for medication - accounting for effectiveness, side effects, convenience, and global satisfaction - that is comparable across medication types and patient conditions. The individual derived score for each of the 4 dimensions (effectiveness, side effects, convenience, and global satisfaction) of the TSQM II questionnaire ranged from 0-100, with a higher score indicating greater satisfaction to treatment.

Time frame:
At Week 12 (Day 84)
Reported as:
Mean · units on a scale
Treatment Satisfaction Questionnaire for Medication Score
units on a scaleLEO 124249LEO 124249 Vehicle
Effectiveness28.9 ± 23.241.7 ± 12.9
Side effects94.5 ± 15.1100.0 ± 0.0
Convenience52.3 ± 17.754.6 ± 21.8
Global satisfaction40.7 ± 22.647.2 ± 22.8

Adverse events

Collected over From screening (within 28 days prior to Day 1) to end of trial (Week 14). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LEO 1242490/20 (0%)0/20 (0%)5/20 (25%)
LEO 124249 Vehicle0/11 (0%)0/11 (0%)2/11 (18.2%)
Most frequent other events
Most frequent other events
EventLEO 124249LEO 124249 Vehicle
FolliculitisInfections and infestations2/200/11
Upper respiratory tract infectionInfections and infestations0/201/11
AlopeciaSkin and subcutaneous tissue disorders1/201/11
ConjunctivitisInfections and infestations1/200/11
LymphadenopathyBlood and lymphatic system disorders1/200/11
FatigueGeneral disorders1/200/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LEO 124249LEO 124249 VehicleTotal
<=18 years000
Between 18 and 65 years201131
>=65 years000
Age, Continuous
Age, Continuous(years)LEO 124249LEO 124249 VehicleTotal
Mean36.4 ± 14.032.1 ± 8.234.9 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)LEO 124249LEO 124249 VehicleTotal
Female14519
Male6612
Region of Enrollment
Region of Enrollment(Participants)LEO 124249LEO 124249 VehicleTotal
United States201131
08

Study locations

2 sites
  • Northwestern University
    Evanston, Illinois 60208, United States
  • The Icahn School of Medicine, Mount Sinai Hospital
    New York, New York 10029, United States
09

References and documents

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2019, 2 years 4 months after primary completion. A results delay was requested in Nov 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2015
First posted
Sep 28, 2015
Start
Jan 2016
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results delay requested
Nov 30, 2017
Results first posted
Apr 16, 2019
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02561585
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Sep 28, 2015
Start date
Jan 2016
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Apr 16, 2019
Last update
Mar 6, 2025

Study contacts

Emma Guttman, MD, PhD
principal investigator · The Icahn School of Medicine, Mount Sinai Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion